Oncoethix starts Phase 1b Trials of OTX015 in the Treatment of Advanced Solid Tumors and Glioma
Oncoethix announced that the first patient has been enrolled in an international, open-label, non-randomized, multicenter Phase 1b trial of OTX015 in advanced solid tumors. The trial will be coordinated by Dr Lillian Siu, MD, of the Princess Margaret Hospital, Toronto, Canada, who is Professor of Medicine at the University of Toronto, and Director of the Phase 1 program.
The trial seeks to enrol up to 98 patients across seven centers in five countries (Belgium, Canada, France, Spain and Switzerland), including the Institut Gustave-Roussy in Paris, where Professor Jean-Charles Soria is the Principal investigator. Three patients have already been enrolled. The trial aims to determine, in a first step, the suitability of five solid tumor indications under investigation (BRD-NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer harbouring a rearrangement ALK gene/fusion protein or KRAS mutation, and Castrate-Resistant Prostate Cancer and Pancreatic Ductal Carcinoma) to be progressed into the Phase 2a part of the trial.
Dr Esteban Cvitkovic, MD, Founder and Chief Scientific Officer, Oncoethix, commented: “This multicenter Phase 1b trial is an important step for OTX015, as it will provide key safety and efficacy data in several solid tumor types, after having characterized its single agent safety and activity profile in the Acute Leukemias and Lymphomas in Phase 1 trial (OTX015_104). The solid tumor indications approach selected for OXT015 is based on compelling data from our own preclinical pharmacology program. We have also initiated a multicentric (France, Switzerland) Phase 2a trial in recurrent glioma.”
OTX015 is a novel first-in-class synthetic small molecule inhibitor of BET bromodomain proteins 2/3/4. These proteins are considered potential cancer targets, as they play a pivotal role in regulating the transcription of growth-promoting and cell cycle regulators.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Epratuzumab data from phase IIb EMBLEM study presented at 9th International Congress on Systemic Lupus Erythematosus
AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis
Immunoglobulin_superfamily
Merck Serono Commits € 1.2 million to the Grant for Fertility Innovation for 2015/16 - Globally, six projects receive funding from this grant cycle
List_of_medical_abbreviations
Tuberculosis Strains Resistant to New Drugs Are Transmitted Between Patients - “We must stay ahead in this constant race between drug development and bacterial resistance...”
Cleanroom infrastructure approaches completion at Vetter’s new Chicago facility
Medical_radiography
Receptor makes mice strong and slim - The corresponding signaling pathways might also exist in humans
The discovery of ancient Salmonella - Oldest reconstructed bacterial genomes link agriculture and herding with emergence of new disease
Organ bioprinting gets a breath of fresh air - Bioengineers clear major hurdle on path to 3D printing replacement organs
